June 26, 2024 08:28 PM EDTUpdated 06:40 AM
R&D
Pharma
FDA+

FDA re­jects Dai­ichi Sanky­o's HER3 ADC, a blow to quick ap­proval plans for Mer­ck part­ner­ship

Kyle LaHucik

Senior Reporter

The FDA has giv­en a thumbs-down to Dai­ichi Sankyo’s HER3 an­ti­body-drug con­ju­gate pa­tri­tum­ab derux­te­can.

The Wednes­day re­jec­tion deals a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times